Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it presented new preclinical data for its anti-cancer compound, Supinoxin™ (RX-5902) at the 38th Annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
The Company’s presentation, entitled “The Anti-Cancer Effects of Supinoxin (RX-5902) in Triple Negative Breast Cancer MDA-MB-231 Through Phosphorylated p68 on Tyr593” was co-authored by Frances Fuller-Pace, Ph.D., Division of Cancer Research, University of Dundee, United Kingdom and Rexahn scientists.
Building on recent data presented by Rexahn at the American Association for Cancer Research Annual Meeting, which demonstrated the ability of Supinoxin to dose-dependently decrease the migration of human triple negative breast cancer cells (MDA-MD-231) in a preclinical model of cancer cell metastasis, Rexahn scientists presented new data at the SABCS showing potent tumor inhibition effects of Supinoxin in a preclinical xenograft mouse model of human triple negative breast cancer (TNBC).
The results demonstrated that oral administration of ascending weekly doses of Supinoxin of 160, 320 and 600 mg/kg showed dose-dependent, potent tumor growth inhibition of 44%, 65% and 83%, respectively, and extended the overall survival of these animals. Moreover, by comparison, 5 mg/kg of Abraxane administered by intravenous injection achieved 50% tumor inhibition.
Dr. Fuller-Pace commented, “The accumulating data for Supinoxin suggest that it targets a unique protein that may play a prominent role in an important biological pathway that leads to the growth and metastasis of cancerous cells and therefore is a promising new potential anti-cancer therapeutic. The current survival and tumor inhibition data in the TNBC model are particularly intriguing as this patient population represents a subset of breast cancer patients with high unmet medical need. We look forward to continuing to build on this promising body of data.”
“We are very pleased to see potent tumor inhibition effects in a well validated preclinical model following oral administration of Supinoxin,” said Dr. Ely Benaim, Chief Medical Officer for Rexahn. “Supinoxin is currently being evaluated in an ongoing Phase I multi-center, dose-finding, open-label, single agent clinical study in patients with advanced or metastatic solid tumors. Recently presented data from the Phase I trial showed promising preliminary evidence of clinical activity. We look forward to additional data from this study.” (Original Source)
Shares of Rexahn Pharmaceuticals closed last Friday at $0.425, down $0.01 or -1.16%. RNN has a 1-year high of $0.96 and a 1-year low of $0.41. The stock’s 50-day moving average is $0.45 and its 200-day moving average is $0.55.
On the ratings front, Roth Capital analyst Joseph Pantginis maintained a Buy rating on RNN, with a price target of $3, in a report issued on November 6. The current price target represents a potential upside of 597.7% from where the stock is currently trading. According to TipRanks.com, Pantginis has a total average return of -5.6%, a 36.7% success rate, and is ranked #3549 out of 3618 analysts.
Rexahn Pharmaceuticals Inc is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs.